Levine v. AtriCure, Inc.

594 F. Supp. 2d 471, 2009 U.S. Dist. LEXIS 6501, 2009 WL 205369
CourtDistrict Court, S.D. New York
DecidedJanuary 28, 2009
Docket1:06-cv-14324-RJH
StatusPublished
Cited by12 cases

This text of 594 F. Supp. 2d 471 (Levine v. AtriCure, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Levine v. AtriCure, Inc., 594 F. Supp. 2d 471, 2009 U.S. Dist. LEXIS 6501, 2009 WL 205369 (S.D.N.Y. 2009).

Opinion

MEMORANDUM OPINION AND ORDER

RICHARD J. HOLWELL, District Judge.

Defendants AtriCure, Inc. (“AtriCure” or the “Company”), David J. Drachman and Thomas Etergino (collectively, “defendants”) move for reconsideration under Local Civil Rule 6.3 of the Court’s September 13, 2007 Memorandum Opinion and Order, see Levine v. AtriCure, Inc., 508 F.Supp.2d 268 (S.D.N.Y.2007), denying their motion to dismiss the complaint or, in the alternative, to certify the Order for interlocutory appeal pursuant to 28 U.S.C. § 1292(6) and to stay proceedings pending any such appeal. For the reasons stated below defendants’ motion is denied.

BACKGROUND

As discussed in greater detail in the September 2007 Opinion, plaintiff purchased shares of AtriCure, a medical device company, in an initial public offering («IPO”) a£ <j£4 per share in August 2005. The purported class action complaint alleges that AtriCure’s Registration Statement was materially misleading because it failed to disclose a damaging conflict of interest arising out of the fact that the Cleveland Clinic, a prestigious hospital that used an AtriCure device, had an interest in the Company through an investment fund and that several of the hospital’s doctors were paid consultants to the Company. (Compl. ¶ 55.) The complaint also alleges that the Wall Street Journal published an article on December 12, 2005 that disclosed the alleged conflict of interest, and that on February 16, 2006 the Company issued a press release stating that it believed it was experiencing a “negative impact” on its business as a result of recent newspaper articles published in December 2005. (Id. ¶¶ 27-28.) In response to this announce *473 ment the price of AtriCure shares declined from $10.36 per share to $8.04 per share. (Id. ¶ 29.) During the period between the August 4, 2005 IPO and the December 12, 2005 Wall Street Journal article, the price of AtriCure shares traded at a high of $14.95/share (on August 11, 2005) and a low of $10.67/share (on October 28, 2005). According to the certification attached to his complaint, plaintiff purchased 250 shares on August 9 at $12.00 per share and sold them at a slight loss ($11.80 per share) on November 21, 2005. The complaint alleges that plaintiff and other members of the purported class sustained damages due to the decline in value of the shares subsequent, and due to, defendants’ misleading registration statement. (Compl. ¶ 38.)

In their motion to dismiss, defendants argued, inter alia, that because plaintiff sold his shares before publication of the Wall Street Journal article he had not plead and could not plead an essential element of his claim under § 11 of the Securities Act of 1933, namely “loss causation.” (Def.’s Mot. to Dismiss Mem. 2-3.) Indeed, according to defendants, the absence of loss causation was apparent on the face of the complaint. (Id.) Further, because plaintiff could not show that his loss was actually caused by the alleged non-disclosures plaintiff also lacked constitutional standing to sue, thus depriving this Court of subject matter jurisdiction. (Id.)

In denying the motion to dismiss the Court, relying on McMahan & Co. v. Wherehouse Entertainment, Inc., 65 F.3d 1044, 1048 (2d Cir.1995), concluded that a plaintiff in a § 11 case is not required to plead or prove loss causation. (See Levine, 508 F.Supp.2d at 272.) Rather, under § 11(e) of the 1933 Act, the absence of loss causation, also known as “negative causation,” is an affirmative defense that is defendants’ burden to plead and prove. (See id. at 272-74.) While declines in the value of shares prior to a corrective disclosure of previously undisclosed information generally will establish negative causation, the complaint did not on its face negate causation and, therefore, defendants’ motion came under the wrong rule (12 instead of 56) and was premature. (Id. at 274.) With respect to the issue of Article III standing, the Court concluded that plaintiffs allegations that he purchased Atri-Cure shares pursuant to a false or misleading registration statement, and that at the time he resold the shares their value had declined, properly alleged injury-in-fact traceable to defendants’ actions as required by Lujan v. Defenders of Wildlife, 504 U.S. 555, 112 S.Ct. 2130, 119 L.Ed.2d 351 (1992), and related cases. (See Levine, 508 F.Supp.2d at 274-76.)

DISCUSSION

1. The Complaint Does Not, Standing on its Own, Establish Negative Causation

After defendants filed their initial memorandum in support of their motion to dismiss, the Supreme Court decided Bell Atlantic v. Twombly 550 U.S. 544, 127 S.Ct. 1955, 167 L.Ed.2d 929 (2007). In Twombly, the Court “retired” the familiar formulation of Conley v. Gibson, 355 U.S. 41, 45-46, 78 S.Ct. 99, 2 L.Ed.2d 80 (1957), that a motion to dismiss must be denied unless “it appears beyond doubt that the plaintiff can prove no set of facts in support of his claim that would entitle him to relief.” In its place, the Court held that while “we do not require heightened fact pleading of specifics,” a complaint must allege “enough facts to state a claim to relief that is plausible on its face.” 127 S.Ct. at 1974. Defendants contend that Twombly imposes a more “stringent” standard of pleading under Rule 8. With a *474 finer point, the Second Circuit after “careful consideration of ... the conflicting signals” in Twombly concluded that the Supreme Court “is not requiring a universal standard of heightened fact pleading, but is instead requiring a flexible ‘plausibility standard,’ which obliges a pleader to amplify a claim with some factual allegations in those contexts where such amplification is needed to render the claim plausible.” Iqbal v. Hasty, 490 F.3d 143, 158 (2d Cir.2007), ce rt. granted sub nom. Ashcroft v. Iqbal, — U.S. -, 128 S.Ct. 2931, 171 L.Ed.2d 863 (2008). Putting aside the question of whether imposition of a “plausibility standard” creates a pleading standard that falls somewhere between what was required by Conley and the more demanding standard of Federal Rule of Civil Procedure 9(b), defendants argue that this Court overlooked Twombly and that its application mandates dismissal of the complaint because plaintiff has not alleged “enough facts” to show that his “claim to relief is plausible on its face.” (Def.’s Recon. Mem. 2 (quoting Twombly, 127 S.Ct.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Alicea v. Smith
D. Connecticut, 2024
Kohl v. Loma Negra Compañia Indus. Argentina S.A.
2022 NY Slip Op 06553 (Appellate Division of the Supreme Court of New York, 2022)
Eric Petzschke v. Century Aluminum Company
704 F.3d 1119 (Ninth Circuit, 2013)
Petzschke v. Century Aluminum Co.
729 F.3d 1104 (Ninth Circuit, 2013)
Wu v. Pearson Education, Inc.
277 F.R.D. 255 (S.D. New York, 2011)
Police & Fire Retirement System v. Safenet, Inc.
645 F. Supp. 2d 210 (S.D. New York, 2009)
In Re Fuwei Films Securities Litigation
634 F. Supp. 2d 419 (S.D. New York, 2009)

Cite This Page — Counsel Stack

Bluebook (online)
594 F. Supp. 2d 471, 2009 U.S. Dist. LEXIS 6501, 2009 WL 205369, Counsel Stack Legal Research, https://law.counselstack.com/opinion/levine-v-atricure-inc-nysd-2009.